Skip to content

US · TKNO · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Alpha Teknova, Inc. (TKNO) intrinsic value and stock valuation

$7.63as of 2026-11-21 · Mkt cap 346.35M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alpha Teknova, Inc. DCF and intrinsic value

InvestorsCraft values TKNO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TKNO’s statements →

Alpha Teknova, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Hollister, CA 95023 teknova.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$40.5M+5.3% 5y CAGRd
20192025
Net income
-$-17.26M
20192025
Free cash flow
-$-9.79M
20192025
Total equity
$68.8M+5.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$40.5M$37.7M$36.7M$41.4M$36.9M
Operating income-$-16.98M-$-26.15M-$-35.56M-$-49.66M-$-12.01M
Net income-$-17.26M-$-26.75M-$-36.78M-$-47.47M-$-9.8M
EPSd-$-322.74K-$-572.19K-$-1.16M-$-1.69M-$-349.88K
Operating cash flow-$-8.65M-$-12.39M-$-18.81M-$-27.4M-$-9.07M
Capital expenditure-$-1.15M-$-1.12M-$-7.93M-$-28.15M-$-19.88M
Free cash flow-$-9.79M-$-13.52M-$-26.75M-$-55.55M-$-28.95M
Total assets$103.6M$118.8M$128.6M$152.3M$166.5M
Total debt$15.2M$30.2M$30.5M$42.3M$11.9M
Net debt$9.23M$26.5M$1.97M$70K-$-75.65M
Total equity$68.8M$82.4M$90M$99.9M$143.2M
Cash and short-term investments$5.91M$30.4M$28.5M$42.2M$87.5M
Income statement
20252024202320222021
Revenue$40.5M$37.7M$36.7M$41.4M$36.9M
Cost of revenue$27.1M$30.5M$26.4M$23.9M$19.3M
Gross profit$13.4M$7.23M$10.3M$17.5M$17.6M
Research and development expenses$2.2M$2.76M$5.57M$7.74M$4.31M
Selling, general and administrative expenses$27.1M$29.5M$34.8M$37.5M$24.2M
Other expenses$1.15M$1.15M$5.51M$22M$1.15M
Operating expenses$30.4M$33.4M$45.9M$67.1M$29.6M
Cost and expenses$57.5M$63.9M$72.3M$91.1M$48.9M
Interest income$0.00$0.00$0.00$210K$0.00
Interest expense$710K$690K$830K$0.00$590K
Depreciation and amortization$6.34M$6.58M$5.66M$3.17M$2.88M
Ebitda-$-10.15M-$-19.57M-$-25.54M-$-25.69M-$-9.16M
Operating income-$-16.98M-$-26.15M-$-35.56M-$-49.66M-$-12.01M
Total other income/expenses, net-$-230K-$-690K-$-1.51M$270K-$-630K
Income before tax-$-17.2M-$-26.83M-$-37.08M-$-49.39M-$-12.64M
Income tax expense$60K-$-90K-$-300K-$-1.92M-$-2.83M
Net income-$-17.26M-$-26.75M-$-36.78M-$-47.47M-$-9.8M
Weighted average shares outstanding$53.5M$46.8M$31.8M$28.1M$28M
Weighted average diluted shares outstanding$53.5M$46.8M$31.8M$28.1M$28M
Balance sheet
20252024202320222021
Cash and short-term investments$5.91M$30.4M$28.5M$42.2M$87.5M
Net receivables$4.62M$4.31M$3.95M$4.28M$5.85M
Inventory$7.05M$6.8M$11.6M$12.3M$5.39M
Total current assets$34.5M$42.8M$45.7M$61.1M$101.2M
Property, plant and equipment, net$55.8M$61.5M$66.8M$71.3M$29.8M
Goodwill and intangible assets$11.9M$13.1M$14.2M$17.6M$35.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$69.1M$76M$82.9M$91.1M$65.3M
Total assets$103.6M$118.8M$128.6M$152.3M$166.5M
Accounts payable$1.38M$820K$1.49M$2.45M$2.25M
Short-term debt$1.88M$5.84M$1.8M$2.22M$0.00
Deferred revenue$0.00$30K$20K$200K$200K
Total current liabilities$7.54M$11.2M$8.88M$10.9M$7.74M
Long-term debt$13.3M$24.3M$28.7M$40.1M$11.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$27.3M$25.2M$29.7M$41.5M$15.6M
Capital lease obligations$0.00$16.7M$17.2M$20.3M$0.00
Total liabilities$34.8M$36.4M$38.6M$52.4M$23.3M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-135.79M-$-118.53M-$-91.79M-$-55.01M-$-7.54M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$68.8M$82.4M$90M$99.9M$143.2M
Total investments$0.00$26.7M$0.00$0.00$0.00
Total debt$15.2M$30.2M$30.5M$42.3M$11.9M
Net debt$9.23M$26.5M$1.97M$70K-$-75.65M
Cash flow statement
20252024202320222021
Net income-$-17.26M-$-26.75M-$-36.78M-$-47.47M-$-9.8M
Depreciation and amortization$6.34M$6.58M$5.66M$3.17M$2.88M
Stock-based compensation$3.43M$3.67M$4.14M$3.71M$1.55M
Change in working capital-$-2.68M-$-870K$2.25M-$-7.33M-$-1.77M
Accounts receivable-$-370K-$-490K$310K$380K-$-50K
Inventory-$-2.37M$240K$330K-$-7.55M-$-2.25M
Accounts payable$470K-$-590K-$-770K$570K$270K
Net cash provided by operating activities-$-8.65M-$-12.39M-$-18.81M-$-27.4M-$-9.07M
Investments in property, plant and equipment-$-1.15M-$-1.12M-$-7.93M-$-28.15M-$-19.88M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$10.7M-$-27.27M-$-7.74M-$-28.15M-$-17.52M
Common stock issued$210K$15.1M$22.5M$440K$102.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$150K$14.9M$12.8M$10.3M$110.8M
Net change in cash$2.2M-$-24.78M-$-13.75M-$-45.28M$84.2M
Cash at end of period$5.91M$3.71M$28.5M$42.2M$87.5M
Operating cash flow-$-8.65M-$-12.39M-$-18.81M-$-27.4M-$-9.07M
Capital expenditure-$-1.15M-$-1.12M-$-7.93M-$-28.15M-$-19.88M
Free cash flow-$-9.79M-$-13.52M-$-26.75M-$-55.55M-$-28.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alpha Teknova, Inc.

        Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.

        CEO
        Stephen Gunstream
        Employees
        158
        Beta
        0.63

        Explore

        Frequently asked questions

        What is the intrinsic value of Alpha Teknova, Inc. (TKNO)?

        Alpha Teknova, Inc. (TKNO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TKNO undervalued?

        TKNO trades at a price of $7.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.